Alliance Pharmaceutical Corp.

Galileo Pharmaceuticals, Inc.

The State University of New York

Stephen F Flaim

Guy M Miller

Sekhar S Boddupalli

Lesley A Brown

Bradley P Fuhrman

Lynn J Hernan

Frances Darey Nesti

Darlene M Dreon

Stephen D Phinney

Michele Cecile Papo

Peggy Beinlich

David Marc Steinhorn

Bing Wang

Jean G Riess

Peter E Keipert

Ughetta Del Balzo

Gwen H Rosenberg

N Simon Faithfull

The present invention provides non-alpha-tocopherol enriched tocopherol compositions and non-alpha-tocopherol metabolite enriched compositions for use in the reduction of inflammatory markers associated with inflammation such as C-reactive protein.

Tocopherol enriched compositions and amelioration of inflammatory symptoms

Non-alpha-tocopherol enriched tocopherol compositions and non-alpha metabolite enriched compositions are disclosed for use in the reduction of the inflammatory marker IL-6.

Tocopherol enriched compositions for reducing IL6 levels

The present invention provides method for the treatment of a symptom of neuronal damage associated with cerebral ischemia comprising administering gamma-, beta-, or delta-tocopherol enriched tocopherol compositions.

Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols

A method of ameliorating tissue damage resulting from hypoxia or ischemia by administering systemically a synthetic oxygen carrier to an individual having or suspected of having blood vessel obstruction is disclosed. A synthetic oxygen carrier in a physiologically acceptable vehicle, wherein the synthetic oxygen carrier comprises submicron sized particles capable of passing through emboli-obstructed blood vessels is also disclosed.

Amelioration of ischemic damage using synthetic oxygen carriers

A method for reducing the inflammatory response in tissues of a patient, by contacting the tissue with an effective, inflammation-reducing amount of a liquid or gaseous fluorocarbon.

Fluorocarbons as anti-inflammatory agents

Biocompatible fluorocarbon emulsions are utilized to inhibit the removal of endogenously produced nitric oxide from the bloodstream, and to thereby inhibit vascular stenosis, vasoconstriction, and any other physiological condition or disorder arising in whole or in part from a deficiency of endogenous nitric oxide.

Liquid fluorocarbon emulsion as a vascular nitric oxide reservoir

A method for reducing the inflammatory response in tissue of a patient, by contacting the tissue with an effective, inflammation-reducing amount of a liquid or gaseous fluorocarbon.

Growing community of inventors

San Diego, CA, United States of America

Stephen F Flaim